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Abstract
Management of ventricular tachycardia (VT) storm in a patient with an implantable cardioverter-
defibrillator (ICD) is a challenging medical emergency. We describe a patient with cardiac 
sarcoidosis (CS) and an ICD who is admitted with VT storm. Management of VT was difficult 
due to resistance to multiple antiarrhythmic drugs. He responded to immunosuppressive therapy 
supporting active CS as the cause of his VT. This case suggests that CS may underlie some cases 
of refractory VT and that immunosuppressive therapy may be effective in controlling this 
arrhythmia.
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Introduction
Sarcoidosis is a disease of unknown etiology and protean manifestations. Cardiac involvement is 
not uncommon. Rhythm disturbances are an important manifestation and can lead to sudden 
cardiac death. We report a patient with CS who presented with ventricular tachycardia storm 
resistant to traditional antiarrhythmics. He responded well to corticosteroids and methotrexate.  
Case   Report                                                                                    
A 46-year-old male with hypertension, type 2 diabetes mellitus and obstructive sleep apnea was 
diagnosed histologically with pulmonary sarcoidosis 5 years previously. He was treated with 
oral prednisone tapered over 6 months. Three years later, he developed Mobitz 1 second-degree 
atrioventricular block. Six months after that he developed congestive heart failure (CHF) with 
left ventricular ejection fraction (LVEF) of 40%. A coronary angiogram did not reveal any 
significant   stenosis.   Cardiac   MRI   showed   concentric   left   ventricular   hypertrophy   with 
hyperenhancement.   Endomyocardial   biopsy   confirmed   extensive   myocardial   sarcoidosis. 
(Figure 1). He had progressive decline of his LVEF to 20% and developed left bundle branch 
block (QRS 165 msec). He was treated with oral prednisone 60mg daily. In light of functional 
class III CHF despite optimal medical therapy, a cardiac re-synchronization ICD (Medtronic 
Concerto CI54DWK) was implanted. Over the next two months, he received six shocks for 
sustained VT and was placed on sotalol 120 mg twice daily with continued oral steroid therapy. 
His CHF symptoms improved and arrhythmia was under control.
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Figure 1. Myocardial biopsy of the patient showing non-caseating granulomas, typical of sarcoidosis
Five months after CRT-D implantation, he was admitted with multiple episodes of VT despite 
being   on   oral   prednisone   30   mg   daily   and   sotalol.   He   was   treated   successfully   with 
antitachycardia pacing 56 times, and he was cardioverted 12 times over the course of 24 hours. 
VT was right bundle inferior axis with negative precordial concordance suggesting an apical 
origin. All episodes of VT were of similar morphology with a cycle length of 300 mSec. 
Lidocaine, mexiletine and amiodarone reduced the frequency of sustained VT episodes, but he 
continued to have episodes of symptomatic non-sustained VT. LVEF was 15-20%. A whole 
body gallium scan demonstrated uptake in the heart consistent with exacerbation of cardiac 
sarcoidosis (Figure 2). High dose intravenous steroid therapy (methylprednisolone 60 mg every 
6 hours) was initiated in place of chronic oral steroid therapy and VT resolved within 12 hours. 
Oral methotrexate was added as a steroid sparing strategy. Sotalol was continued and other 
antiarrhythmics were stopped. Three days later, he was discharged on methotrexate (15mg/week 
PO) and a tapering dose of oral prednisone. At 3 and 6 months follow-up visits, his CHF was 
compensated with an LVEF of 25-30% and he was free of ventricular tachycardia on device 
interrogation. Repeat gallium scan at 6 months showed no significant uptake in the heart.
Discussion
Management of arrhythmias in CS is difficult and effective control of VT often is not achievable 
by a single method of therapy. Acute inflammation with new granuloma formation that can disrupt 
myocardial fibers together with the patchy scarring associated with old healed granulomas can 
provide a substrate for new VT reentrant circuits. Antiarrhythmic drugs can facilitate occurrence 
of VT, as well as aggravate conduction abnormalities. Hypercalcemia, inherent to sarcoidosis; 
hypokalemia from concurrent corticosteroid use, as well as the interaction between acute phase 
reactants and antiarrhythmics can further complicate drug therapy [1].                                   
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Optimal therapy of ventricular arrhythmia associated with CS is not well established. Various 
regimens including corticosteroids, antiarrhythmic medications, ICDs and catheter ablations have 
been attempted. Steroids improved overall mortality in CS [2]. Steroids are believed to be capable 
of   attenuating   the   inflammatory   response   and   slowing   subsequent   fibrosis.   Although 
corticosteroids help in suppressing arrhythmia secondary to sarcoid exacerbation, they may be of 
little use in the management of VT from scarred myocardium. This can explain the recurrence of 
VT despite treatment with corticosteroids in previously reported cases [3-4]. Active sarcoid 
exacerbation may cause VT in patients who are already on treatment with moderate to high doses 
of corticosteroids as seen in this patient. Immunosuppressive therapies are recommended as a 
steroid sparing strategy in the management of sarcoidosis and can be beneficial in controlling 
arrhythmia.
Figure 2. Gallium-67 whole-body scan of the patient showing intense uptake in heart and mediastinum.
A stepwise approach in the management this malignant arrhythmia was studied [5]. ICD 
implantation, immunosuppression with corticosteroids, then up to two antiarrhythmic drugs were 
used (in that order) before patients were taken to the EP lab for mapping and ablation. 9 of the 21 
patients with sustained VT underwent ablation. 44 VTs were induced and 31 were ablated. VT 
burden was reduced more than 98% in the first 3 months post ablation. The mechanism of VT in 
virtually   all   patients   was   re-entry   [5-6].                                                        
Cardiac Resynchronization Therapy (CRT), which is an adjunct treatment to pharmacological 
therapy in patients with advanced heart failure, may have potential proarrhythmic effects [7]. 
Although rare, CRT has been shown to cause VT [8] and electrical storm [9]. Most CRT 
associated ventricular proarrhythmia was seen in ischemic cardiomyopathy patients soon after 
biventricular pacing lead implantation, and improved with cessation of biventricular pacing [8-9]. 
This patient tolerated CRT well for months. The presence of extensive myocardial sarcoidosis and 
lack of recurrent VT during the follow-up period despite continued CRT makes CRT related 
proarrhythmia an unlikely mechanism of VT in our patient. Electrophysiology study with ablation 
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can be undertaken in CS, but VT circuits can change as inflammation waxes and wanes. VT may 
be ablated only to reoccur as the substrate shifts. Ablation should be considered as an option in 
those patients with recurrent VT that are unresponsive to antiarrhythmic and immunosuppressive 
drugs.
Conclusion
Cardiac sarcoidosis related arrhythmia can be very difficult to manage. Because of increased 
awareness of the risk of sudden cardiac death and early ICD implantation, CS patients can survive 
to present with VT storm, which is not uncommonly resistant to standard antiarrhythmic drugs. 
While corticosteroids are mainstay of therapy to control the acute inflammation and hence related 
arrhythmia, immunosuppressive therapy such as methotrexate should be considered early if steroid 
resistance develops and before proceeding to catheter ablation.                                       
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